CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; and Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC.

Please visit answersincme.com/TBY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in colorectal cancer discuss management of patients with metastatic disease in the third line and beyond. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatments for patients with metastatic colorectal cancer (mCRC); Review the clinical implications of the latest evidence for later-line treatments for patients with mCRC; and Outline evidence-based approaches to improve long-term response rates in later-line treatment of mCRC.

Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy in the neoadjuvant treatment of early HR-positive, HER2-negative breast cancer; Identify the clinical implications of the latest data for neoadjuvant treatment with immunotherapy plus chemotherapy regimens in early HR-positive, HER2-negative breast cancer; Describe the role that neoadjuvant, immunotherapy-containing regimens might play in the future management of patients with early HR-positive, HER2-negative breast cancer, including high risk patients.

Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.

Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.

Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.

Please visit answersincme.com/DMQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the role of CELMoDs in overcoming IMiD resistance in earlier lines of therapy for multiple myeloma. Upon completion of this activity, participants should be better able to: Explain the biologic rationale for investigating novel CELMoDs in earlier lines of therapy in patients with multiple myeloma (MM); Review the clinical significance of late-stage trials of emerging CELMoDs in the maintenance and earlier-relapse settings in patients with MM; and Outline the clinical considerations for integrating novel CELMoDs in the maintenance and earlier-relapse settings in the future treatment landscape of MM.

Please visit answersincme.com/AEP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses strategies to integrate novel anti-CD38 monoclonal antibody (mAb)-based triplet regimens into care plans for patients with early relapse multiple myeloma (MM). Upon completion of this activity, participants should be better able to: Review the latest evidence-based guideline recommendations for the treatment of early relapse MM; Outline the clinical implications of the latest evidence for anti-CD38 mAb-based triplet regimens in the treatment of early relapse MM; and Identify strategies to optimally integrate novel anti-CD38 mAb-based triplet regimens into treatment plans for patients with early relapse MM.